The treatment of cancer, especially of various types of solid tumors, has been revolutionized by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success amongst hematologic malignancies, however, has been limited so far to the treatment of classic Hodgkin's lymphoma, which portrays a typical overexpression of PD-1 ligands (PD-L1, PD-L2) as a consequence of changes in chromosome 9p24.1. Their current application in multiple myeloma (MM) is rather uncertain, as discordant results have been reported by distinct research groups concerning especially the expression of PD-1/PD-L1 molecules on malignant plasma cells or on the responsible immune effector cell populations, respectively. In MM it seems that an approach based on combination treatment might be appropriate as unsatisfactory results have been yielded by monotherapy with PD-1/PD-L1 inhibitors. Immunomodulatory drugs, which are the current cornerstone of MM treatment, are the most logical partners as they possess many possibly synergistic effects. Nevertheless, the initially optimistic results have become disappointing due to the excessive and unpredictable toxicity of the combination of pembrolizumab with lenalidomide or pomalidomide. The FDA has suspended or put on hold several phase 3 trials in relapsed as well as in newly diagnosed myeloma patients. There are also other potentially synergistic and promising combinations, such as the anti-CD38 monoclonal antibody daratumumab, irradiation, etc. Not only the effective partner but also the correct timing of the initiation of the PD-1/PD-L1 inhibitors treatment seems to be of utmost importance. These strategies are currently being examined in various stages of myeloma such as during consolidation post autologous stem cell transplantation, targeting minimal residual disease or even in high risk smoldering myeloma.

Centro de Investigación Médica Aplicada Clínica Universidad de Navarra IDISNA Pamplona Spain

Department of Haematooncology University Hospital Ostrava Ostrava Czechia

Faculty of Medicine University of Ostrava Ostrava Czechia

Faculty of Science University of Ostrava Ostrava Czechia

Zobrazit více v PubMed

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. (2011) 364:1046–60. 10.1056/NEJMra1011442 PubMed DOI

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. (2014) 15:e538–48. 10.1016/S1470-2045(14)70442-5 PubMed DOI

Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. . Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. (2007) 356:2582–90. 10.1056/NEJMoa070389 PubMed DOI

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. (2014) 64:9–29. 10.3322/caac.21208 PubMed DOI

Maluskova D, Svobodová I, Kucerova M, Brozova L, Muzik J, Jarkovský J, et al. . Epidemiology of multiple myeloma in the Czech Republic. Klin Onkol Cas Ceske Slov Onkol Spolecnosti (2017) 30:35–42. 10.14735/amko20172S35 PubMed DOI

Lahuerta J-J, Paiva B, Vidriales M-B, Cordón L, Cedena M-T, Puig N, et al. . Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. (2017) 35:2900–10. 10.1200/JCO.2016.69.2517 PubMed DOI PMC

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. . Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. (2015) 372:142–52. 10.1056/NEJMoa1411321 PubMed DOI

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. . Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. (2016) 374:1621–34. 10.1056/NEJMoa1516282 PubMed DOI

San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. (2013) 14:1055–66. 10.1016/S1470-2045(13)70380-2 PubMed DOI

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. (2015) 373:621–31. 10.1056/NEJMoa1505654 PubMed DOI

San-Miguel JF, Hungria VTM, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, et al. . Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. (2014) 15:1195–206. 10.1016/S1470-2045(14)70440-1 PubMed DOI

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. . Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. (2015) 373:1207–19. 10.1056/NEJMoa1506348 PubMed DOI

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. . Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. (2016) 375:1319–31. 10.1056/NEJMoa1607751 PubMed DOI

Mateos M-V, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. . Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. (2017) 378:518–28. 10.1056/NEJMoa1714678 PubMed DOI

Jelinek T, Hajek R. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Blood Rev. (2016) 30:101–10. 10.1016/j.blre.2015.08.004 PubMed DOI

Jelínek T, Korístka M, Cermáková Z, Hájek R. Daratumumab-hope for myeloma patients, a challenge for clinical laboratories. Klin Onkol Cas Ceske Slov Onkol Spolecnosti (2017) 30:13–9. 10.14735/amko201713 PubMed DOI

Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, et al. . A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood (2017) 129:3294–303. 10.1182/blood-2016-09-740787 PubMed DOI PMC

Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology (2017) 152:357–71. 10.1111/imm.12788 PubMed DOI PMC

Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood (1996) 87:1196–8. PubMed

Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al. Safety and efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with cyclophosphamide conditioning for refractory Multiple Myeloma (MM). Blood (2017) 130:505 Available online at: www.bloodjournal.org/content/130/Suppl_1/505

Berdeja JG, Lin Y, Raje N, Munshi N, Siegel D, Liedtke M, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 Anti-Bcma CAR T cell therapy. Blood (2017) 130:740 Available online at: http://www.bloodjournal.org/content/130/Suppl_1/740

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. . Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell (2017) 31:396–410. 10.1016/j.ccell.2017.02.002 PubMed DOI

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252–64. 10.1038/nrc3239 PubMed DOI PMC

Armand P. Immune checkpoint blockade in hematologic malignancies. Blood (2015) 125:3393–400. 10.1182/blood-2015-02-567453 PubMed DOI

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. . Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. (2015) 373:123–35. 10.1056/NEJMoa1504627 PubMed DOI PMC

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. (2015) 373:23–34. 10.1056/NEJMoa1504030 PubMed DOI PMC

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. (2015) 373:1803–13. 10.1056/NEJMoa1510665 PubMed DOI PMC

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. (2015) 372:311–9. 10.1056/NEJMoa1411087 PubMed DOI PMC

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. (1992) 11:3887–95. PubMed PMC

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. (2000) 192:1027–34. 10.1084/jem.192.7.1027 PubMed DOI PMC

Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. . Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. (2003) 33:3117–26. 10.1002/eji.200324270 PubMed DOI

Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. . CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. (2005) 25:9543–53. 10.1128/MCB.25.21.9543-9553.2005 PubMed DOI PMC

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature (2017) 545:495–9. 10.1038/nature22396 PubMed DOI PMC

Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 116:2286–94. 10.1182/blood-2010-02-271874 PubMed DOI PMC

Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. . Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood (2007) 110:296–304. 10.1182/blood-2006-10-051482 PubMed DOI

Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. . Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia (2013) 27:464–72. 10.1038/leu.2012.213 PubMed DOI

Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. . Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia (2015) 29:1441–4. 10.1038/leu.2015.11 PubMed DOI PMC

Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. . Lenalidomide Enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. (2015) 21:4607–18. 10.1158/1078-0432.CCR-15-0200 PubMed DOI PMC

Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, et al. . Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood (2015) 126:2475–8. 10.1182/blood-2015-03-632919 PubMed DOI PMC

Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, et al. . PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia (2015) 29:2110–3. 10.1038/leu.2015.79 PubMed DOI

Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, et al. . Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia (2018) 32:230–3. 10.1038/leu.2017.272 PubMed DOI PMC

Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. . Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell (2009) 16:309–23. 10.1016/j.ccr.2009.08.019 PubMed DOI PMC

Sponaas A-M, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, et al. . PDL1 Expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PLoS ONE (2015) 10:e0139867. 10.1371/journal.pone.0139867 PubMed DOI PMC

Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, et al. . PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother Hagerstown Md 1997 (2011) 34:409–18. 10.1097/CJI.0b013e31821ca6ce PubMed DOI PMC

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. . Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28:iv52–61. 10.1093/annonc/mdx096 PubMed DOI

Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. (2016) 99:249–60. 10.1016/j.critrevonc.2016.01.004 PubMed DOI

Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. (2012) 36:1218–24. 10.1016/j.leukres.2012.05.010 PubMed DOI

Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget (2017) 8:24031–44. 10.18632/oncotarget.15234 PubMed DOI PMC

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, et al. . PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv. (2017) 1:753–65. 10.1182/bloodadvances.2017004382 PubMed DOI PMC

Chen L, Byers LA, Ullrich S, Wistuba II, Qin X-F, Gibbons DL. CD38 as a Novel Immune Checkpoint and a Mechanism of Resistance to the Blockade of the PD-1/PD-L1 Axis. (Orlando, FL: ), Abstract 79, Oral abstract. Available online at: https://meetinglibrary.asco.org/record/144495/abstract (Accessed August 22, 2018).

Bezman NA, Kinder M, Jhatakia AD, Mattson BK, Pizutti D, Thompson EW, et al. Abstract 1727: antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models. Cancer Res. (2018) 78:1727 10.1158/1538-7445.AM2018-1727 DOI

Jelinek T, Hajek R. PD-1/PD-L1 inhibitors in multiple myeloma: the present and the future. OncoImmunology (2016) 5:e1254856. 10.1080/2162402X.2016.1254856 PubMed DOI PMC

Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. (2015) 16:e498–509. 10.1016/S1470-2045(15)00007-8 PubMed DOI

Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell (2015) 27:437–8. 10.1016/j.ccell.2015.03.015 PubMed DOI

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, et al. . Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 520:373–7. 10.1038/nature14292 PubMed DOI PMC

Binder DC, Fu Y-X, Weichselbaum RR. Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med. (2015) 21:463–5. 10.1016/j.molmed.2015.05.007 PubMed DOI

Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol Baltim Md 1950 (2013) 190:5620–8. 10.4049/jimmunol.1202005 PubMed DOI PMC

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. . Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. (2016) 34:2698–704. 10.1200/JCO.2015.65.9789 PubMed DOI PMC

Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, et al. . T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. (2016) 4:61–71. 10.1158/2326-6066.CIR-15-0055 PubMed DOI PMC

Hallett WHD, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant (2011) 17:1133–45. 10.1016/j.bbmt.2011.03.011 PubMed DOI

Ribrag V, Avigan DE, Martinelli G, Green DJ, Trisha W-D, Posada JG, et al. PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA…In Siegel D, Editor. Poster Presentation, Abstract: P344. Madrid. (2018). Available online at: https://learningcenter.ehaweb.org/eha/2017/22nd/181631/vincent.ribrag.pembrolizumab.monotherapy.for.relapsed.refractory.multiple.htmlf=m3e1181l15532 (Accessed May 2, 2018).

Rodriguez-Otero P, Mateos M-V, Orlowski R, Siegel D, Reece D, Moreau P, Miguel JS. PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR…In: Rodriguez-Otero P, Editors. Oral Presentation, Abstract: S783. Madrid. (2018). Available online at: https://learningcenter.ehaweb.org/eha/2017/22nd/182070/paula.rodriguez-otero.pembrolizumab.plus.lenalidomide.and.low-dose.htmlf=media=3 (Accessed May 2, 2018).

Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, et al. . Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood (2017) 130:1189–97. 10.1182/blood-2017-03-775122 PubMed DOI

Biran N, Andrews T, Feinman R, Vesole DH, Richter JR, Zenreich J, Anand P, McBride L, Ivanovski K, Korngold R, et al. A phase II trial of the anti -PD-1 monoclonal antibody pembrolizumab (MK-3475) + lenalidomide + dexamethasone as post autologous stem cell transplant consolidation in patients with high-risk multiple myeloma. Blood (2017) 130:1831 Available online at: http://www.bloodjournal.org/content/130/Suppl_1/1831

Pawarode A, D'Souza A, Pasquini MC, Johnson B, Braun T, Dhakal B, et al. Phase 2 Study of pembrolizumab during lymphodepleted state after autologous hematopoietic cell transplantation in multiple myeloma patients. Blood (2017) 130:339 Available online at: http://www.bloodjournal.org/content/130/Suppl_1/339

Ocio EM, Puig N, Corchete L, Pérez JJ, Dávila J, Paíno T, et al. Immune predictors of response to pembrolizumab monotherapy as consolidation in multiple myeloma patients: results of the GEM-Pembresid clinical trial. Blood (2017) 130:1874 Available online at: http://www.bloodjournal.org/content/130/Suppl_1/1874 PubMed

Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, Popa-Mckiver M, Farsaci B, Zhu L, Lesokhin AM, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood (2016) 128:183 Available online at: http://www.bloodjournal.org/content/128/22/183

Skarbnik AP, Donato ML, Rowley SD, Goy A, Vesole DH, Munshi PN, et al. Preliminary safety and efficacy data for combined checkpoint inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 trial. Blood (2017) 130:340 Available online at: http://www.bloodjournal.org/content/130/Suppl_1/340 PubMed

Efebera YA, Rosko A, Hofmeister CC, Benner J, Bakan C, Benson DM. Paper: First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. Orlando, IL: Available online at: https://ash.confex.com/ash/2015/webprogram/Paper81417.html (Accessed July 25, 2016).

Rosenblatt J, Avivi I, Binyamini N, Uhl L, Somayia P, Stroopinsky D, et al. Paper: Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease. Orlando, IL: Available online at: https://ash.confex.com/ash/2015/webprogram/Paper80695.html (Accessed July 25, 2016).

Mateos M-V, Blacklock H, Schjesvold F, Rocafiguera AO, Simpson D, Lonial S. A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183. In: Poster session, Abstract 8021. Chicago, IL: (2018). Available online at: https://meetinglibrary.asco.org/record/161606/abstract (Accessed August 22, 2018).

Usmani SZ, Schjesvold F, Rocafiguera AO, Karlin L, Rifkin RM, San-Miguel J. A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185. In: Poster Discussion Session, Abstract 8010. Chicago, IL: (2018). Available online at: https://meetinglibrary.asco.org/record/160702/abstract (Accessed August 22, 2018).

Manasanch EE, Mathur R, Lee HC, Weber DM, Patel KK, Thomas SK, et al. Pilot study of pembrolizumab for immunoprevention in smoldering multiple myeloma. Blood (2017) 130:3089 Available online at: http://www.bloodjournal.org/content/130/Suppl_1/3089

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. (2002) 3:991–8. 10.1038/ni1102-991 PubMed DOI

Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. (2015) 33:2092–9. 10.1200/JCO.2014.60.0379 PubMed DOI PMC

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. . Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. (2015) 26:2375–91. 10.1093/annonc/mdv383 PubMed DOI PMC

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28:iv119–42. 10.1093/annonc/mdx225 PubMed DOI

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. (2018) 378:158–68. 10.1056/NEJMra1703481 PubMed DOI

Krauss AC, Mulkey F, Shen Y-L, Rosenberg A, Miller B, Spring S. FDA Analysis of Pembrolizumab Trials in Multiple Myeloma: Immune Related Adverse Events (irAEs) and Response. Chicago, IL: Available online at: https://meetinglibrary.asco.org/record/160685/abstract (Accessed August 22, 2018).

Martinez-Calle N, Rodriguez-Otero P, Villar S, Mejías L, Melero I, Prosper F, et al. . Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica (2018) 103:e318–21. 10.3324/haematol.2017.185777 PubMed DOI PMC

Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, et al. . Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia (2016) 30:1716–24. 10.1038/leu.2016.84 PubMed DOI

Tremblay-LeMay R, Rastgoo N, Chang H. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. J Hematol OncolJ Hematol Oncol. (2018) 11:46. 10.1186/s13045-018-0589-1 PubMed DOI PMC

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies